Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

Nature Reviews Cancer

Volumn 6, Issue 1, 2006, Pages 38-51

  Minucci, Saverio ^a,b   Pelicci, Pier Giuseppe ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; APICIDIN; ARYLBUTYRIC ACID DERIVATIVE; BENZAMIDE DERIVATIVE; BUTYRIC ACID; CARBOXYLIC ACID DERIVATIVE; CYCLOPEPTIDE; DOCETAXEL; FR 901228; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; KETONE DERIVATIVE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PIVALOYLOXYMETHYL BUTYRATE; SULFONAMIDE; TRICHOSTATIN A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VALPROIC ACID; VORINOSTAT;

ACETYLATION; ANEMIA; ANOREXIA; APOPTOSIS; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER THERAPY; CARCINOGENESIS; CARDIOTOXICITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DEACETYLATION; DEHYDRATION; DIARRHEA; DNA BINDING; DNA DAMAGE; DNA PACKAGING; DRUG DEGRADATION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME REGULATION; ENZYME STRUCTURE; ENZYME SUBSTRATE; EPIGENETICS; FATIGUE; GENE CONTROL; GENE MUTATION; HEART ARRHYTHMIA; HUMAN; LEUKEMIA; LUNG CANCER; LYMPHOMA; MELANOMA; MOLECULAR MECHANICS; MYELODYSPLASIA; NAUSEA AND VOMITING; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REVIEW; RNA INTERFERENCE; SOLID TUMOR; T CELL LYMPHOMA; TACHYCARDIA; THROMBOCYTOPENIA; TRANSCRIPTION INITIATION; TRANSCRIPTION TERMINATION; UTERINE CERVIX CANCER;

EPIGENESIS, GENETIC; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HUMANS; NEOPLASMS;

EID: 30344477367     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1779     Document Type: Review

References (141)

1. Blander, G. & Guarente, L. The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 73, 417-435 (2004).
2. Gregoretti, I. V., Lee, Y. M. & Goodson, H. V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338, 17-31 (2004). An insightful phylogenetic analysis of HDACs.
3. Leipe, D. D. & Landsman, D. Histone deacetylases, acetoin utilization proteins and acetylpolyamine amidohydrolases are members of an ancient protein superfamily. Nucleic Acids Res. 25, 3693-3997 (1997).
4. Kouzarides, T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 19, 1176-1179 (2000).
5. Richmond, T. J. & Davey, C. A. The structure of DNA in the nucleosome core. Nature 423, 145-150 (2003).
6. Strahl, B. D. & Allis, C. D. The language of covalent histone modifications. Nature 403, 41-45 (2000).
7. Turner, B. M. Cellular memory and the histone code. Cell 111, 285-291 (2002). References 6 and 7 contain the proposal and one of the counter-proposals of the histone code.
8. Turner, B. M. Reading signals on the nucleosome with a new nomenclature for modified histones. Nature Struct. Mol. Biol. 12, 110-112 (2005).
9. Allfrey, V. G., Faulkner, R. & Mirsky, A. E. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl Acad. Sci. USA 51, 786-794 (1964).
10. Polo, S. E. & Almouzni, G. Histone metabolic pathways and chromatin assembly factors as proliferation markers. Cancer Lett. 220, 1-9 (2005).
11. Vidanes, G. M., Bonilla, C. Y. & Toczyski, D. P. Complicated tails: histone modifications and the DNA damage response. Cell 121, 973-976 (2005).
12. Weinreich, M., Palacios DeBeer, M. A. & Fox, C. A. The activities of eukaryotic replication origins in chromatin. Biochim. Biophys. Acta 1677, 142-157 (2004).
13. Zhang, J., Xu, F., Hashimshony, T., Keshet, I. & Cedar, H. Establishment of transcriptional competence in early and late S phase. Nature 420, 198-202 (2002).
14. Mann, M. & Jensen, O. N. Proteomic analysis of post-translational modifications. Nature Biotechnol. 21, 255-261 (2003).
15. Qiang, L., Xiao, H., Campos, E. I., Ho, V. C. & Li, G. Development of a PAN-specific, affinity-purified anti-acetylated lysine antibody for detection, identification, isolation, and intracellular localization of acetylated protein. J. Immunoassay Immunochem. 26, 13-23 (2005).
16. Ronzoni, S., Faretta, M., Ballarini, M., Pelicci, P. & Minucci, S. New method to detect histone acetylation levels by flow cytometry. Cytometry A 66A, 52-61 (2005).
17. Caron, C., Boyault, C. & Khochbin, S. Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability. Bioessays 27, 408-415 (2005).
18. Giandomenico, V., Simonsson, M., Grönroos, E. & Ericsson, J. Coactivator-dependent acetylation stabilizes members of the SREBP family of transcription factors. Mol. Cell. Biol. 23, 2587-2599 (2003).
19. Grönroos, E., Hellman, U., Heldin, C. H. & Ericsson, J. Control of Smad7 stability by competition between acetylation and ubiquitination. Mol. Cell 10, 483-493 (2002).
20. Jin, Y. H. et al. Transforming growth factor-β stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J. Biol. Chem. 279, 29409-29417 (2004).
21. Rausa, F. M., Hughes, D. E. & Costa, R. H. Stability of the hepatocyte nuclear factor 6 transcription factor requires acetylation by the CREB-binding protein coactivator. J. Biol. Chem. 279, 43070-43076 (2004).
22. Munshi, N et al. Coordination of a transcriptional switch by HMGI(Y) acetylation. Science 293, 1133-1136 (2001).
23. Yuan, Z. L., Guan, Y. J., Chatterjee, D. & Chin, Y. E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307, 269-273 (2005).
24. Wang, R., Cherukuri, P. & Luo, J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J. Biol. Chem. 280, 11528-11534 (2005).
25. Jeong, J. W. et al. Regulation and destabilization of HIF-1α by ARD1-mediated acetylation. Cell 111, 709-7020 (2002).
26. Bilton, R. et al. Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1α and is not induced by hypoxia or HIF. J. Biol. Chem. 280, 31132-31140 (2005).
27. Cohen HY, et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol. Cell 13, 627-638 (2004). Cytoplasmic role for acetylation of Ku70 in apoptosis.
28. Cohen, H. Y. et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305, 390-392 (2004).
29. Bonaldi, T. et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22, 5551-5560 (2003).
30. Bannister, A. J., Miska, E. A., Görlich, D. & Kouzarides, T. Acetylation of importin-α nuclear import factors by CBP/p300. Curr. Biol. 10, 467-470 (2000).
31. Caillaud, A. et al. Acetylation of interferon regulatory factor-7 by p300/CREB-binding protein (CBP)-associated factor (PCAF) impairs its DNA binding. J. Biol. Chem. 277, 49417-49421 (2002).
32. Choi, C. H., Hiromura, M. & Usheva, A. Transcription factor IIB acetylates itself to regulate transcription. Nature 424, 965-969 (2003).
33. Hasan, S. et al. Acetylation regulates the DNA end-trimming activity of DNA polymerase β. Mol. Cell 10, 1213-1222 (2002).
34. Hasan, S. et al. Regulation of human flap endonuclease-1 activity by acetylation through the transcriptional coactivator p300. Mol. Cell 7, 1221-1231 (2001).
35. Bode, A. M. & Dong, Z. Post-translational modification of p53 in tumorigenesis. Nature Rev. Cancer 4, 793-805 (2004).
36. Chen, L. F. & Greene, W. C. Shaping the nuclear action of NF-κB. Nature Rev. Mol. Cell Biol. 5, 392-401 (2004).
37. Kawaguchi, Y. et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115, 727-738 (2003).
38. Kovacs, J. J. et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18, 601-607 (2005). Role of acetylation in the control of the chaperone function of HSP90.
39. Lagger, G. et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J. 21, 2672-2681 (2002). Genetic demonstration that HDAC1 is essential for proliferation in mammals.
40. Zhang, C. L. et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110, 479-488 (2002).
41. Vega, R. B. et al. Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis. Cell 119, 555-566 (2004).
42. Minucci, S., Nervi, C., Lo Coco, F. & Pelicci, P. G. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20, 3110-3115 (2001).
43. Warrell, R. P. et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med. 324, 1385-1393 (1991).
44. Minucci, S. & Pelicci, P. G. Retinoid receptors in health and disease: co-regulators and the chromatin connection. Semin. Cell Dev. Biol. 10, 215-225 (1999).
45. Lin, R. J., Egan, D. A. & Evans, R. M. Molecular genetics of acute promyelocytic leukemia. Trends Genet 15, 179-184 (1999).
46. Lin, R. J. & Evans, R. M. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol. Cell 5, 821-830 (2000).
47. Minucci, S. et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol. Cell 5, 811-820 (2000).
48. Di Croce, L. et al. Altered epigenetic signals in human disease. Cancer Biol. Ther. 3, 831-837 (2004).
49. Di Croce, L. et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295, 1079-1082 (2002).
50. He, L. Z. et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest 108, 1321-1330 (2001).
51. Brown, D. et al. A PMLRARα transgene initiates murine acute promyelocytic leukemia. Proc. Natl Acad. Sci. USA 94, 2551-2556 (1997).
52. Grisolano, J. L., Wesselschmidt, R. L., Pelicci, P. G. & Ley, T. J. Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR α under control of cathepsin G regulatory sequences. Blood 89, 376-387 (1997).
53. Trecca, D. et al. Analysis of p53 gene mutations in acute myeloid leukemia. Am. J. Hematol. 46, 304-309 (1994).
54. Insinga, A., Pelicci, P. G. & Minucci, S. Leukemia-associated fusion proteins. Multiple mechanisms of action to drive cell transformation. Cell Cycle 4, 67-69 (2005).
55. Insinga, A. et al. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J. 23, 1144-1154 (2004). Demonstrates that deacetylation of non-histone substrates (p53) by HDACs has a role in tumorigenesis.
56. Bereshchenko, O. R., Gu, W. & Dalla-Favera, R. Acetylation inactivates the transcriptional repressor BCL6. Nature Genet. 32, 606-613 (2002).
57. Eckner, R., Arany, Z., Ewen, M., Sellers, W. & Livingston, D. M. The adenovirus E1A-associated 300-kD protein exhibits properties of a transcriptional coactivator and belongs to an evolutionary conserved family. Cold Spring Harb. Symp. Quant. Biol. 59, 85-95 (1994).
58. Iyer, N. G., Ozdag, H. & Caldas, C. p300/CBP and cancer. Oncogene 23, 4225-4231 (2004).
59. Kumar, R., Wang, R. A. & Bagheri-Yarmand, R. Emerging roles of MTA family members in human cancers. Semin. Oncol. 30, 30-37 (2003).
60. Bagheri-Yarmand, R., Talukder, A. H., Wang, R. A., Vadlamudi, R. K. & Kumar, R. Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development 131, 3469-3479 (2004).
61. Zhu, P. et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5, 455-463 (2004).
62. Toh, Y. et al. Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int. J. Cancer 110, 362-367 (2004).
63. Fraga, M. F. et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genet. 37, 391-400 (2005). References 62 and 63 demonstrate that global histone modifications occur in cancer.
64. Seligson, D. B. et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435, 1262-1266 (2005). A coordinated pattern of histone modifications predicts clinical outcome in prostate cancer.
65. Egger, G., Liang, G., Aparicio, A. & Jones, P. A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457-463 (2004).
66. Feinberg, A. P. & Tycko, B. The history of cancer epigenetics. Nature Rev. Cancer 4, 143-153 (2004).
67. Lund, A. H. & van Lohuizen, M. Epigenetics and cancer. Genes Dev. 18, 2315-2335 (2004).
68. Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Rev. Drug Discov. 1, 287-299 (2002).
69. Marks, P. et al. Histone deacetylases and cancer: causes and therapies. Nature Rev. Cancer 1, 194-202 (2001).
70. Mai, A. et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med. Res. Rev. 25, 261-309 (2005).
71. Miller, T. A., Witter, D. J. & Belvedere, S. Histone deacetylase inhibitors. J. Med. Chem. 46, 5097-5116 (2003).
72. Park, J. H. et al. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin. Cancer Res. 10, 5271-5281 (2004).
73. Mai, A. et al. Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. J. Med. Chem. 46, 4826-4829 (2003).
74. Heltweg, B. et al. Subtype selective substrates for histone deacetylases. J. Med. Chem. 47, 5235-5243 (2004).
75. Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M. & Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl Acad. Sci. USA 100, 4389-4394 (2003).
76. Finnin, M. S. et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401, 188-193 (1999).
77. Richon, V. M. et al. Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivo. Methods Enzymol. 376, 199-205 (2004).
78. Somoza, J. R. et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure (Camb) 12, 1325-1334 (2004).
79. Vannini, A. et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl Acad. Sci. USA 101, 15064-15069 (2004). References 78 and 79 show the structural analysis of mammalian HDAC8 in complex with HDACi.
80. Siddiqui, H., Solomon, D. A., Gunawardena, R. W., Wang, Y. & Knudsen, E. S. Histone deacetylation of RB-responsive promoters: requisite for specific gene repression but dispensable for cell cycle inhibition. Mol. Cell. Biol. 23, 7719-7731 (2003).
81. Glaser, K. B. et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol. Cancer Ther. 2, 151-163 (2003).
82. Mitsiades, C. S. et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc. Natl Acad. Sci. USA 101, 540-545 (2004).
83. Peart, M. J. et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102, 3697-3702 (2005).
84. Van Lint, C., Emiliani, S. & Verdin, E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 5, 245-253 (1996). References 81-84 detail gene-profiling studies of the cell transcriptional response to HDACi in different model systems. The results are not always fully consistent among the different systems (the number of modulated genes varies from < 5% to 20%).
85. Camphausen, K. et al. Enhanced radiation-induced cell killing and prolongation of γH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res. 64, 316-321 (2004).
86. Munshi, A. et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin. Cancer Res. 11, 4912-4922 (2005).
87. Warrener, R. et al. Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J. 17, 1550-1552 (2003).
88. Beamish, H., Warrener, R. & Gabrielli, B. G. Analysis of checkpoint responses to histone deacetylase inhibitors. Methods Mol. Biol. 281, 245-259 (2004).
89. Qiu, L. et al. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol. Biol. Cell 11, 2069-2083 (2000).
90. Richon, V. M., Sandhoff, T. W., Rifkind, R. A. & Marks, P. A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl Acad. Sci. USA 97, 10014-10019 (2000).
91. Gui, C. Y., Ngo, L., Xu, W. S, Richon, V. M. & Marks, P. A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl Acad. Sci. USA 101, 1241-1246 (2004).
92. Varshochi, R. et al. ICI182,780 induces p21 Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor α from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line. J. Biol. Chem. 280, 3185-3196 (2005).
93. Archer, S. Y., Meng, S., Shei, A. & Hodin, R. A. p21 (WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl Acad. Sci. USA 95, 6791-6796 (1998).
94. Shao, Y., Gao, Z., Marks, P. A. & Jiang, X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 101, 18030-18035 (2004).
95. Rosato, R. R., Almenara, J. A., Grant, S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 63, 3637-3645 (2003).
96. Ungerstedt, J. S. et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102, 673-678 (2005).
97. Subramanian, C., Opipari, A. W., Bian, X., Castle, V. P. & Kwok, R. P. Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102, 4842-4847 (2005).
98. Atadja, P. et al. Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. Novartis Found. Symp. 259, 249-266 (2004).
99. Bali, P. et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280, 26729-26734 (2005).
100. Hideshima, T. et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc. Natl Acad. Sci. USA 102, 8567-8572 (2005).
101. Insinga, A. et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nature Med. 11, 71-76 (2005).
102. Nebbioso, A. et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nature Med. 11, 77-84 (2005). References 101 and 102 demonstrate the essential role of induction of the TRAIL pathway for the pro-apoptotic response following HDACi treatment in leukaemias.
103. Inoue, H. et al. Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis. Int. J. Mol. Med. 9, 521-525 (2002).
104. Nakata, S. et al. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 23, 6261-6271 (2004).
105. Singh, T. R., Shankar, S. & Srivastava, R. K. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene 24, 4609-4623 (2005).
106. Watanabe, K., Okamoto, K. & Yonehara, S. Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death Differ. 12, 10-18 (2005).
107. Rosato, R. R. & Grant, S. Histone deacetylase inhibitors in clinical development. Expert Opin. Investig. Drugs 13, 21-38 (2004).
108. Johnstone, R. W. & Licht, J. D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4, 13-18 (2003).
109. Drummond, D. C. et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 45, 495-528 (2004).
110. Chavez-Blanco, A. et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol. Cancer 4, 22 (2005).
111. Kelly, W. K. et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23, 3923-3931 (2005).
112. Kelly, W. K. et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9, 3578-3588 (2003).
113. Ryan, Q. C. et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 23, 3912-3922 (2005).
114. Piekarz, R. L. et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98, 2865-2868 (2001).
115. Sandor, V. et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8, 718-728 (2002).
116. Piekarz, R. L. et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103, 4636-4643 (2004).
117. Bandyopadhyay, D., Mishra, A. & Medrano, E. E. Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res. 64, 7706-7710 (2004).
118. Xiao, J. J. et al. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8, 20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J. Pharmacol. Exp. Ther. 314, 467-475 (2005).
119. Pilatrino, C. et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 104, 101-109 (2005).
120. Cameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G. & Baylin, S. B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genet. 21, 103-107 (1999).
121. + cells sensitive and resistant to STI571 (imatinib mesylate) in association with downregulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. Mol. Pharmacol. 67, 1166-1176 (2005).
122. Girdwood, D. W., Tatham, M. H. & Hay, R. T. SUMO and transcriptional regulation. Semin. Cell Dev. Biol. 15, 201-210 (2004).
123. Al-Hajj, M., Becker, M. W., Wicha, M., Weissman, I. & Clarke, M. F. Therapeutic implications of cancer stem cells. Curr. Opin. Genet. Dev. 14, 43-47 (2004).
124. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
125. Milhem, M. et al. Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A. Blood 103, 4102-4110 (2004). An initial study on the effects of HDACi on stem cells.
126. Guenther, M. G. et al. A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness. Genes Dev. 14, 1048-1057 (2000).
127. Huang, E. Y. et al. Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes Dev. 14, 45-54 (2000).
128. Humphrey, G. W. et al. Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1. J. Biol. Chem. 276, 6817-6824 (2001).
129. Jones, P. L., Sachs, L. M., Rouse, N., Wade, P. A. & Shi, Y. B. Multiple N-CoR complexes contain distinct histone deacetylases. J. Biol. Chem. 276, 8807-8811 (2001).
130. Li, J. et al. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J. 19, 4342-4350 (2000).
131. Xue, Y. et al. NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Mol. Cell 2, 851-861 (1998).
132. Yao, Y. L. & Yang, W. M. The metastasis-associa ted proteins 1 and 2 form distinct protein complexes with histone deacetylase activity. J. Biol. Chem. 278, 42560-42568 (2003).
133. Zhang, Y. et al. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 13, 1924-1935 (1999).
134. Seigneurin-Berny, D. et al. Identification of components of the murine histone deacetylase 6 complex: link between acetylation and ubiquitination signaling pathways. Mol. Cell. Biol. 21, 8035-8044 (2001).
135. Yamagoe, S. et al. Interaction of histone acetylases and deacetylases in vivo. Mol. Cell. Biol. 23, 1025-1033 (2003).
136. Fischle, W. et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 9, 45-57 (2002).
137. Verdin, E., Dequiedt, F. & Kasler, H. G. Class II histone deacetylases: versatile regulators. Trends Genet. 19, 286-293 (2003).
138. Gore, S. D. et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 8, 963-970 (2002).
139. Patnaik, A. et al. A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin. Cancer Res. 8, 2142-2148 (2002).
140. Raffoux, E., Chaibi, P., Dombret, H. & Degos, L. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 90, 986-988 (2005).
141. Byrd, J. C. et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105, 959-967 (2005).